キュアバックは臨床腫瘍学者であり,薬剤開発の専門家であるメヒディ・シャヒディ博士を独立取締役に任命した. CureVac appoints clinical oncologist and drug development expert Dr. Mehdi Shahidi as independent director.

mRNA技術の先駆者であるCureVacは,臨床腫瘍学者であり,薬の開発の経験豊富な専門家であるMehdi Shahidi博士を,独立取締役に任命しました. CureVac, a pioneer in mRNA technology, has appointed Dr. Mehdi Shahidi, a clinical oncologist and experienced drug development expert, as an independent director on its Supervisory Board. シャヒディ博士は現在,ペタリオン・セラピュティクス社のCEOであり,メディクシのベンチャーパートナーを務めています. Dr. Shahidi currently serves as CEO of Petalion Therapeutics and a Venture Partner at Medicxi. 幹部リーダーシップ,医薬品開発,臨床腫瘍学における彼の豊富な経験は,CureVacの技術革新と研究開発,特に新しい世代のmRNAベースのがんワクチン開発に焦点を強めます. His extensive experience in executive leadership, drug development, and clinical oncology will strengthen CureVac's focus on technology innovation and R&D, particularly in the development of a new generation of mRNA-based cancer vaccines.